A Healing Promotion Wound Dressing with Tailor-made Antibacterial Potency employing piezocatalytic processes in multi-functional nanocomposites

Nanoscale ◽  
2022 ◽  
Author(s):  
Yi Zhang ◽  
Qi An ◽  
Shuting Zhang ◽  
Zequn Ma ◽  
Xiantong Hu ◽  
...  

Developing novel antibiotics-free antibacterial strategy is essential for minimizing bacterial resistance. Materials not only kill bacterial but also promote tissue healing are especially challenging to achieve. Inspired by chemical conversion...

2020 ◽  
Author(s):  
Benedict Hew ◽  
Qiao Wen Tan ◽  
William Goh ◽  
Jonathan Wei Xiong Ng ◽  
Kenny Koh ◽  
...  

AbstractBacterial resistance to antibiotics is a growing problem that is projected to cause more deaths than cancer in 2050. Consequently, novel antibiotics are urgently needed. Since more than half of the available antibiotics target the bacterial ribosomes, proteins that are involved in protein synthesis are thus prime targets for the development of novel antibiotics. However, experimental identification of these potential antibiotic target proteins can be labor-intensive and challenging, as these proteins are likely to be poorly characterized and specific to few bacteria. In order to identify these novel proteins, we established a Large-Scale Transcriptomic Analysis Pipeline in Crowd (LSTrAP-Crowd), where 285 individuals processed 26 terabytes of RNA-sequencing data of the 17 most notorious bacterial pathogens. In total, the crowd processed 26,269 RNA-seq experiments and used the data to construct gene co-expression networks, which were used to identify more than a hundred uncharacterized genes that were transcriptionally associated with protein synthesis. We provide the identity of these genes together with the processed gene expression data. The data can be used to identify other vulnerabilities or bacteria, while our approach demonstrates how the processing of gene expression data can be easily crowdsourced.


Molecules ◽  
2020 ◽  
Vol 25 (7) ◽  
pp. 1543 ◽  
Author(s):  
Buthaina Jubeh ◽  
Zeinab Breijyeh ◽  
Rafik Karaman

Bacterial resistance to present antibiotics is emerging at a high pace that makes the development of new treatments a must. At the same time, the development of novel antibiotics for resistant bacteria is a slow-paced process. Amid the massive need for new drug treatments to combat resistance, time and effort preserving approaches, like the prodrug approach, are most needed. Prodrugs are pharmacologically inactive entities of active drugs that undergo biotransformation before eliciting their pharmacological effects. A prodrug strategy can be used to revive drugs discarded due to a lack of appropriate pharmacokinetic and drug-like properties, or high host toxicity. A special advantage of the use of the prodrug approach in the era of bacterial resistance is targeting resistant bacteria by developing prodrugs that require bacterium-specific enzymes to release the active drug. In this article, we review the up-to-date implementation of prodrugs to develop medications that are active against drug-resistant bacteria.


RSC Advances ◽  
2016 ◽  
Vol 6 (73) ◽  
pp. 69103-69116 ◽  
Author(s):  
Poornima Dubey ◽  
P. Gopinath

Designing composite nanomaterials that display multiple antibacterial mechanisms offers new prototypes against bacterial resistance.


RSC Advances ◽  
2015 ◽  
Vol 5 (33) ◽  
pp. 25870-25876 ◽  
Author(s):  
Shengping Gao ◽  
Wei Ge ◽  
Chunqiu Zhao ◽  
Chuansheng Cheng ◽  
Hui Jiang ◽  
...  

It is well known that nanosilver or silver ions could act as an effective antibacterial agent without the development of bacterial resistance but long term exposure may induce in vivo toxicity.


RSC Advances ◽  
2015 ◽  
Vol 5 (55) ◽  
pp. 44666-44678 ◽  
Author(s):  
Baljit Singh ◽  
Abhishek Dhiman

Recently, it has been found that moxifloxacin, an antibiotic drug, promotes wound healing without induction to bacterial resistance.


Planta Medica ◽  
2015 ◽  
Vol 81 (11) ◽  
Author(s):  
N Adnani ◽  
E Vazquez-Rivera ◽  
S Adibhatla ◽  
GA Ellis ◽  
D Braun ◽  
...  

2018 ◽  
Author(s):  
Paolo Madeddu

The year 2018 marked the 110th anniversary of Goldmann’s discovery that vascularization is an active process in tissues1 and the 50th anniversary of the concomitant reports from Greenblatt and Shubik2 and Ehrmann and Knoth3 that soluble morphogenic factors are required for cancer angiogenesis. Many other radically transformative paradigms have been introduced in the last decades. To name a few, the molecular search for the identity of master regulators of vascular tone led to the discovery of the Endothelium-Derived Relaxing Factor (EDRF; i.e., NO4), while clinically inspired investigations led to the recognition of the pathophysiological relevance of neoangiogenesis in cancer and tissue healing. This brought about the proposal of blocking angiogenesis to halt tumor growth and stimulating angiogenesis to treat myocardial ischemia and heart failure5-7.


Sign in / Sign up

Export Citation Format

Share Document